CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 3.31: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.55%
Annual Rate
USD 0.25Paid annual
Payout Ratio
71.4%Moderate
Paying Dividends
2 yr
Payback Period
29.1 yr
Last Ex-Dividend
Mar 23, 2026
Last Payment
Apr 7, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
406.74MUSDvs all stocks (USD)
Trailing P/E
20.14xRevenue (TTM)
181.68MUSDvs all stocks (USD)
Profit Margin
11.21%Beta
0.1540xvs all stocks
52-Week Change
-9.62%vs all stocks
Market Capitalization
406.74MUSDvs all stocks (USD)
Enterprise Value
345.18MUSDvs all stocks (USD)
Trailing P/E
20.14xForward P/E
11.49xPrice to Sales (TTM)
2.24xPrice to Book (MRQ)
1.57xEnterprise to Revenue
1.90xEnterprise to EBITDA
8.87xGross Margin
42.25%Profit Margin
11.21%Operating Margin
15.37%Return on Assets (TTM)
4.19%Return on Equity (TTM)
7.97%Revenue (TTM)
181.68MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.12USDUpdated Jul 19, 2026Quarterly Revenue Growth
2.80%Gross Profit (TTM)
74.77MUSDvs all stocks (USD)
EBITDA (TTM)
39.71MUSDvs all stocks (USD)
Net Income (TTM)
20.37MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.20%Operating Cash Flow (TTM)
25.71MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
11.08MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.2500USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
3.55%vs all stocks
Payout Ratio
71.43%Revenue
180.46MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
104.05MUSDFY2025 · Dec 31, 2025Gross Profit
76.41MUSDFY2025 · Dec 31, 2025Operating Income
26.23MUSDvs all stocks (USD)
Pre-tax Income
23.47MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.27MUSDFY2025 · Dec 31, 2025Net Income
20.20MUSDFY2025 · Dec 31, 2025EBIT
24.33MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
40.42MUSDFY2025 · Dec 31, 2025Research & Development
12.99MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
33.84MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.92MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
864.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
0.3500USDFY2025 · Dec 31, 2025EPS (Diluted)
0.3500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
57.71MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
57.71MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
20.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
23.36MUSDFY2025 · Dec 31, 2025Free Cash Flow
13.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
75.47MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
20.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
14.92MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
3.27MUSDFY2025 · Dec 31, 2025Stock-based Compensation
845.00KUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.77MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-5.47MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.87MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.29MUSDFY2025 · Dec 31, 2025Capital Expenditures
-9.84MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-9.84MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-972.00KUSDFY2025 · Dec 31, 2025Common Dividends Paid
-11.53MUSDFY2025 · Dec 31, 2025Other Financing Charges
-5.89MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-18.39MUSDFY2025 · Dec 31, 2025Shares Outstanding
57.69MSharesUpdated Jul 19, 2026Float Shares
31.45MSharesUpdated Jul 19, 2026Shares Short
153.34KSharesUpdated Jul 19, 2026Short Ratio
3.61daysvs all stocks
Short % of Shares Outstanding
0.49%vs all stocks
% Held by Insiders
7.20%vs all stocks
% Held by Institutions
48.60%vs all stocks
Total Cash (MRQ)
73.15MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.27USDUpdated Jul 19, 2026Total Debt (MRQ)
11.64MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0449xCurrent Ratio (MRQ)
3.33xBook Value per Share (MRQ)
4.50USDUpdated Jul 19, 2026Total Assets
378.71MUSDvs all stocks (USD)
Total Current Assets
193.07MUSDFY2025 · Dec 31, 2025Total Liabilities
109.64MUSDFY2025 · Dec 31, 2025Total Non-current Assets
185.63MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
62.25MUSDFY2025 · Dec 31, 2025Total Current Liabilities
47.39MUSDFY2025 · Dec 31, 2025Cash
38.22MUSDFY2025 · Dec 31, 2025Cash Equivalents
37.25MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
75.47MUSDFY2025 · Dec 31, 2025Accounts Receivable
27.01MUSDFY2025 · Dec 31, 2025Inventory
84.94MUSDFY2025 · Dec 31, 2025Accounts Payable
23.24MUSDFY2025 · Dec 31, 2025Short-term Debt
2.12MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
9.92MUSDFY2025 · Dec 31, 2025Long-term Debt
9.44MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
50.48MUSDFY2025 · Dec 31, 2025Common Stock (Book)
15.08MUSDFY2025 · Dec 31, 2025Retained Earnings
-17.07MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
269.07MUSDvs all stocks (USD)
52-Week Low
6.50USDUpdated Jul 19, 202652-Week High
9.35USDUpdated Jul 19, 202652-Week Change
-9.62%vs all stocks
Beta
0.1540xvs all stocks
50-Day MA
7.54USDUpdated Jul 19, 2026200-Day MA
7.70USDUpdated Jul 19, 2026Avg 10-Day Volume
30.36KSharesUpdated Jul 19, 2026Avg 30-Day Volume
36.28KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.3500USDUpdated Jul 19, 2026Other Income / Expense
-3.82MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.31: safe zoneNotable
Altman Z-Score: 3.31
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Century Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule